Compare TLS & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | OCGN |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.6M | 387.3M |
| IPO Year | 2020 | N/A |
| Metric | TLS | OCGN |
|---|---|---|
| Price | $4.37 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $7.75 | $7.00 |
| AVG Volume (30 Days) | 652.7K | ★ 4.4M |
| Earning Date | 03-09-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $144,400,000.00 | $5,370,000.00 |
| Revenue This Year | $52.26 | $35.88 |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.44 | 14.26 |
| 52 Week Low | $1.83 | $0.52 |
| 52 Week High | $8.36 | $1.96 |
| Indicator | TLS | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 45.98 |
| Support Level | $4.23 | $1.36 |
| Resistance Level | $5.12 | $1.48 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 11.18 | 30.88 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").